An American Journal of Managed Care® Symposium: Examining Treatment Advancements in Psoriasis and Psoriatic Arthritis

Substantial savings opportunities exist by using lower-cost biologics for patients with plaque psoriasis, according to one study.

August is National Psoriasis Awareness Month, and on this episode of Managed Care Cast, we bring you an excerpt of an interview with a New Jersey dermatologist about the changing concept of psoriasis as more than just a skin disease.

Biologics for psoriasis had lower drug survival in women compared with men, according to one study.

Posters presented at the 2025 American Academy of Dermatology Annual Meeting found tildrakizumab outcomes to have a mean drug survival of almost 3 years.

Posters presented at the 2025 American Academy of Dermatology Annual Meeting found bimekizumab to have benefits beyond safety and efficacy findings.

Biologics targeting interleukin (IL)-12, IL-23, or IL-17 reduced serious infections, while tofacitinib increased infection risk, according to one study.